Clinical Trials in Liver Transplantation

Massachusetts General Hospital Transplant Center patients have access to leading-edge clinical trials and therapies, including immunosuppression withdrawal and new Hepatitis C treatments.

Researchers isolate islet cells

Support Us

To learn more about how you can support the Mass General Transplant Center, contact James F. Markmann, MD, PhD, at 617-643-4533

To make a gift now, please contact Tyrone C. Latin in Mass General Development at 617-643-5781 or make a donation online

Immunosuppression Withdrawal
In spite of advances over the last 50 years in anti-rejection medications, the side effects of long-term immunosuppressive therapy remain a major problem for post-transplant patients. Mass General has been a leader in developing protocols to allow transplant patients to live drug-free and without rejection.

For more information about immunosuppression withdrawal studies for liver transplant recipients, call 617-726-2631.
Hepatitis C TreatmentHepatitis C infection can return after liver transplantation, occasionally causing liver damage severe enough to require re-transplantation. The Liver Transplant Program at the Mass General Transplant Center offers the latest FDA-approved anti-viral therapies and participates in clinical trials utilizing promising new agents.

For more information about hepatitis C clinical trials, call 617-724-3836.

patient

Innovations in transplant training and research

Learn about the exceptional research and training opportunities offered by the kidney and islet transplant programs at Mass General.